Should I buy Molina Healthcare (MOH) stock or is it too late?
⭐ The most reliable of them, either direction: Truist Securities — 64% of its targets hit on this sector (109 calls tested). It aims for $225 (+13 %), call made on July 25, 2026, maturing on July 25, 2027 (34 d ago).
Firm-by-firm track record on Molina Healthcare
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Morgan Stanley | 75 % | +29.3 % | 24 | $167 -16% |
| JP Morgan | 55 % | +23.8 % | 11 | $191 -4% |
| Jefferies | 64 % | +8.9 % | 11 | $169 -15% |
| B of A Securities | 69 % | +6.7 % | 13 | $439 +121% |
| Mizuho | 56 % | -0.4 % | 9 | $180 -9% |
| Truist Securities | 45 % | -9.0 % | 11 | $225 +13% |
| Wells Fargo | 38 % | -11.0 % | 13 | $220 +11% |
| Cantor Fitzgerald | 18 % | -27.1 % | 11 | $209 +5% |
✅ Reasons to believe
- Few solid positives from analysts right now: of 11 ratings, only 1 buys, and the median price target ($202) is barely above the price (+2%, at $199). Caution prevails.
⚠️ Reasons to hesitate
- Even the most reliable firm on MOH, Morgan Stanley (75% hit rate, 24 scored calls), only targets $167 (call made on June 4, 2026, maturing on June 4, 2027) (-16%) in its most recent call, and $204 (call made on October 14, 2025, maturing on October 14, 2026) (+3%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 11 ratings, 9 are neutral and 1 is a sell.
- Limited upside: the median target is only +2% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on MOH
Median target $202 (+2%) · 11 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Molina Healthcare now?
We won't decide for you. The facts: 9% of analysts rate it a buy, median target $202 (+2%), and Morgan Stanley (most reliable on MOH, 75%) targets $167. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Molina Healthcare?
The stated upside is small: the median target ($202) sits just +2% from the price ($199) (most reliable on MOH: Morgan Stanley, 75%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Molina Healthcare still worth investing in?
It depends on the gap between the price ($199) and its estimated value: analysts target $202 on median (+2%), with 9% buys (most reliable on MOH: Morgan Stanley, 75%). Cross-check with their real reliability on MOH and the cautions above. Information, not advice.
What's the main risk in buying MOH?
Even the most reliable firm on MOH, Morgan Stanley (75% hit rate, 24 scored calls), only targets $167 (call made on June 4, 2026, maturing on June 4, 2027) (-16%) in its most recent call, and $204 (call made on October 14, 2025, maturing on October 14, 2026) (+3%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Molina Healthcare profile (consensus, analyst reliability, price target, performance).